DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Cancer immunotherapy
Cancer immunotherapy
And High-Dose Cyclophosphamide
Intratumoral Immunotherapy for Early Stage Solid Tumors
AN ANTICANCER DRUG COCKTAIL of Three Kinase Inhibitors Improved Response to a DENDRITIC CELL–BASED CANCER VACCINE
07052020 MR ASCO20 Curtain Raiser
Rheumatic Immune-Related Adverse Events—A Consequence of Immune Checkpoint Inhibitor Therapy
Key Enzymes in Cancer: Mechanism of Action and Inhibition with Anticancer Agents
Immunostimulatory Effects of Low-Dose Cyclophosphamide Are Controlled by Inducible Nitric Oxide Synthase
Best Practices for Implementing Cancer Immunotherapy in the Community
A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers
Immunotherapy an Inhibitor Of
Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
Current Trends in Cancer Immunotherapy
Immune-Related Adverse Events Associated with Cancer
US10851148.Pdf
Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy
Comparator Report on Cancer in Europe 2019 −Disease Burden, Costs and Access to Medicines
Cancer Immunotherapy
Characteristics of the Japanese Pharmaceutical Market: Implications for the Direction of Pharmaceutical Companies’ Research and Development Strategy
Top View
Co-Stimulatory Versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia
Comparator Report on Patient Access to Cancer Medicines in Europe Revisited
A Guide to Cancer Immunotherapy: from T Cell Basic Science to Clinical Practice
Treating Non-Hodgkin Lymphoma If You’Ve Been Diagnosed with Non-Hodgkin Lymphoma, Your Treatment Team Will Discuss Your Options with You
Cgas/STING Axis Mediates a Topoisomerase II Inhibitor-Induced Tumor Immunogenicity
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
Cladribine Induces ATF4 Mediated Apoptosis and Synergizes with SAHA In
Poster EHAP 2019
Classic Cancer Therapies Activate Cgas
Targeting Cancer with Kinase Inhibitors
Immunotherapy in Patients with Autoimmune Disease
Photodynamic Immunotherapy of Cancers Based on Nanotechnology
Modul 2(Pdf 586,39
Immune Modulation by Chemotherapy Or Immunotherapy to Enhance Cancer Vaccines
How Immunotherapy Is Used to Treat Cancer
PD-L1 Immunotherapy
Personalized Chordoma Organoids for Drug Discovery Studies
Immunotherapy Side Effects: Immune Checkpoint Inhibitors, 2020 1 About
A Phase II Evaluation of Pembrolizumab in Combination with IV Bevacizumab and Oral Metronomic Cyclophosphamide in The
Horizon Scanning in Oncology
Photodynamic Therapy—Current Limitations and Novel Approaches
Co-Delivery of IOX1 and Doxorubicin for Antibody-Independent Cancer
Cancer Immunotherapy.Pdf
Increased Cytoplasmatic Expression of Cancer Immune Surveillance Receptor Cd1d in Anaplastic Thyroid Carcinomas
Interfaces Between Cellular Responses to DNA Damage and Cancer Immunotherapy
Cancer Immunotherapy
The London School of Economics and Political Science Cancer Medicines
Cladribine Induces ATF4 Mediated Apoptosis and Synergizes With
Combining the Oncolytic Peptide LTX-315 with Doxorubicin Demonstrates Therapeutic Potential in a Triple-Negative Breast Cancer Model Ketil A
NTRC Case Biomarker Discovery for CDK4/6 Inhibitors.Indd
Targeting Immunotherapy for Bladder Cancer by Using Anti-CD3 × CD155
Cancer Immunotherapy: Successes and Pitfalls for the Non-Oncologist Daniel W
PATIENT RESOURCE Monoclonal Antibodies
Immunotherapy and Cancer – Making the Past Prologue
Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors
Basic Principles of Cancer Immunotherapy
Immunotherapy and Combined Chemotherapy for Castration
An Anticancer Drug Cocktail of Three Kinase Inhibitors Improved Response to a Dendritic Cell–Based Cancer Vaccine Jitao Guo1, Elena Muse1, Allison J
Doxorubicin-Loaded PLGA Nanoparticles for Cancer Therapy: Molecular Weight Effect of PLGA in Doxorubicin Release for Controlling Immunogenic Cell Death
Targeting Immunogenic Cancer Cell Death by Photodynamic Therapy: Past, Present and Future
Antitumor Drugs and Their Targets
T-Cell Dysfunction in Chronic Lymphocytic Leukemia from An
Venetoclax Increases Intra-Tumoral Effector T Cells and Anti-Tumor Efficacy in Combination with Immune Checkpoint Blockade
Personalized Healthcare in Oncology: Past, Present and Future
Immunotherapy in Advanced Prostate Cancer
Understanding Cancer Immunotherapy
Immunotherapy As a Precision Medicine Tool for the Treatment of Prostate Cancer
My Journey from Tyrosine Phosphorylation Inhibitors to INAUGURAL ARTICLE Targeted Immune Therapy As Strategies to Combat Cancer
Cancer Immunotherapy Guidelines (Prostate)
Synergistic Antitumor Effects of Topoisomerase Inhibitors And
Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors
Danske Kræftforskningsdage 29
Immunogenicity of Externally Activated Nanoparticles for Cancer Therapy
Recent Advances in Photodynamic Therapy for Deep-Seated Tumors with the Aid of Nanomedicine
Ibrutinib Combinations in CLL Therapy: Scientific Rationale and Clinical Results
Immune-Based Mechanisms of Cytotoxic Chemotherapy: Implications for the Design of Novel and Rationale-Based Combined Treatments Against Cancer
Treating Waldenstrom Macroglobulinemia If You’Ve Been Diagnosed with Waldenstrom Macroglobulinemia, Your Treatment Team Will Discuss Your Options with You
1 Doxorubicin Eliminates Myeloid-Derived Suppressor Cells
Immunotherapy to Treat Malignancy in Patients with Pre-Existing Autoimmunity
NDD Pipeline Overview
Role of 4-1BB:4-1BB Ligand in Cancer Immunotherapy
Synergistic and Low Adverse Effect Cancer Immunotherapy by Immunogenic Chemotherapy and Locally Expressed PD-L1 Trap
Targeting Topoisomerase I in the Era of Precision Medicine
Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives Through Clinical Trials Outcomes
Nivolumab (OPDIVO®)
Public Summary of Opinion on Orphan Designation Venetoclax for the Treatment of Mantle Cell Lymphoma